Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cancer drugs pricing

- PMLiVE

Flexible working: a fad or the future?

As the Flexible Working Bill gets written into UK law, we took a look at what this means for businesses of all sizes and specialities.

Cuttsy + Cuttsy

Icons of hand holding brain and lightbulb lighting up with brain inside

Looking for a job head first

During Health Information Week, we reflected on mental health and wellbeing within the workplace. Cuttsy+Cuttsy’s mental health first aider and HR Manager, Kate McCabe, shared some thoughts on what mental...

Cuttsy + Cuttsy

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

- PMLiVE

Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Novartis acquires DTx Pharma in deal worth up to $1bn

The agreement gives Novartis access to three preclinical neuroscience programmes

Mobilizing Agitation Detection in Children with ADHD

Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...

Impetus Digital

- PMLiVE

Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

The transaction includes the Swiss drugmaker’s anti-inflammatory eye drop Xiidra

- PMLiVE

Novartis to acquire Chinook Therapeutics for approximately $3.5bn

The deal marks a notable expansion to the Swiss drugmaker's kidney disease pipeline

- PMLiVE

Healing the Healers

Because if we do not heal the healers, who is going to heal us?

Havas Lynx

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

EU flag

EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug

The EU regulator concluded that the benefits of Adakveo did not outweigh its risks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links